Tagged with Antitrust

Potential Impacts of the US Antitrust Environment on Biopharmaceutical M&A

USA Potential Impacts of the US Antitrust Environment on Biopharmaceutical M&A

USA David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions. Crean expects to see a continuation of 2023’s strong start to M&A and questions whether the FTC’s newly-aggressive approach will…